HIV Integrase Inhibitors
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 20 4975
(15) Barreca, M. L.; Ferro, S.; Rao, A.; Luca, L. D.; Zappala, M.;
Monforte, A. M.; Debyser, Z.; Witvrouw, M.; Chimirri, A. Pharma-
cophore-based design of HIV-1 strand transfer inhibitors. J. Med.
Chem. 2005, 48, 7084-7088.
(16) Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinage,
T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R.
Structure of the HIV-1 integrase catalytic domain complexed with
an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad.
Sci. U.S.A. 1999, 96, 13040-13043.
(17) Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J.
S.; Zhuang, L.; Fisher, T. E.; Embrey, M.; Guare, J. P.; Egbertson,
M. S.; Vacca, J. P.; Huff, J. R.; Felock, P. J.; Witmer, M. V.;
Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M. D.; Espeseth,
A. S.; Jin, L.; Chen, I. W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.;
Wong, B. K.; Xu, W.; Pearson, P. G.; Schleif, W. A.; Cortese, R.;
Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D. A naphthy-
ridine carboxamide provides evidence for discordant resistance
between mechanistically identical inhibitors of HIV-1 integrase. Proc.
Natl. Acad. Sci. U.S.A. 2004, 101, 11233-11238.
(18) Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez,
R. P.; Wai, J. S.; Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.;
Dornadula, G.; Danovich, R. M.; Witmer, M. V.; Wilson, K. A. A.;
Tussey, L.; Schleif, W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.;
Casimiro, D. R.; Emini, E. A.; Shiver, J. W. Integrase inhibitors and
cellular immunity suppress retroviral replication in rhesus macaques.
Science 2004, 305, 528-532.
(19) Summa, V.; Petrocchi, A.; Pace, P.; Matassa, V. G.; De Francesco,
R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of alpha,
gamma-diketoacids as potent selective and reversible inhibitors of
hepatitis C virus NS5B RNA-dependent RNA Polymerase. J. Med.
Chem. 2004, 47, 14-17.
(20) Pace, P.; Nizi, E.; Pacini, B.; Pesci, S.; Matassa, V.; De Francesco,
R.; Altamura, S.; Summa, V. The monoethyl ester of meconic acid
is an active site inhibitor of HCV NS5B RNA-dependent RNA
polymerase. Bioorg. Med. Chem. Letters 2004, 14, 3257-3261.
(21) Crescenzi, B.; Poma, M.; Ontoria, J. M.; Marchetti, A.; Nizi, E.;
Matassa, V. G.; Gardelli, C. Phenyldihydroxypyrimidines as HCV
NS5B RNA dependent RNA polymerase inhibitors. Part I: Amides
and ureas. Lett. Drug Des. DiscoVery 2005, 2, 451-455.
(22) Koch, U.; Attenni, B.; Malancona, S.; Colarusso, S.; Conte, I.; Di,
Filippo, M.; Harper, S.; Pacini, B.; Giomini, C.; Thomas, S.; Incitti,
I.; Tomei, L.; De Francesco, R.; Altamura, S.; Matassa, V. G.; Narjes,
F. 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors
of the hepatitis C virus NS5B polymerase: Discovery, SAR,
modeling, and mutagenesis. J. Med. Chem. 2006, 49, 1693-1705.
(23) Ponzi, S.; Giuliano, C.; Donghi, M.; Poma, M.; Matassa, V. G.;
Stansfield, I. Phenyldihydroxypyrimidines as HCV NS5B RNA
dependent RNA polymerase inhibitors. Part II: Sulfonamides. Lett.
Drug Des. DiscoVery 2005, 2, 456-461.
(24) Stansfield, I.; Avolio, S.; Colarusso, S.; Gennari, N.; Narjes, F.; Pacini,
B.; Ponzi, S.; Harper, S. Active site inhibitors of HCV NS5B
polymerase. The development and pharmacophore of 2-thienyl-5,6-
dihydroxypyrimidine-4-carboxylic acid. Bioorg. Med. Chem. Lett.
2004, 14, 5085-5088.
(25) Summa, V.; Petrocchi, A.; Matassa, V. G.; Taliani, M.; Laufer, R.;
De Francesco, R.; Altamura, S.; Pace, P. HCV NS5B RNA-dependent
RNA polymerase inhibitors: From R,γ-diketoacids to 4,5-dihydroxy-
pyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids.
Design and synthesis. J. Med. Chem. 2004, 47, 5336-5339.
(26) Summa, V.; Petrocchi, A.; Matassa, V. G.; Gardelli, C.; Muraglia,
E.; Rowley, M.; Gonzalez, Paz, O.; Laufer, R.; Monteagudo, E.; Pace,
P. 4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxy-
pyrimidinone carboxamides are potent, selective HIV integrase
inhibitors with good pharmacokinetic profile in preclinical species.
J. Med. Chem. 2006, 49, 6646-6649.
(27) Petrocchi, A.; Koch, U.; Matassa, V. G.; Pacini, B.; Stillmock, K.
A.; Summa, V. From dihydroxypyrimidine carboxylic acids to
carboxamide HIV-1 integrase inhibitors; SAR around the amide
moiety. Bioorg. Med. Chem. Lett. 2007, 17, 350-353.
(28) Boffito, M.; Back, D. J.; Blaschke, T. F.; Rowland, M.; Bertz, R. J.;
Gerber, J. G.; Miller, V. Protein binding in antiretroviral therapies.
AIDS Res. Hum. RetroViruses 2003, 19, 825-835.
(29) Pace, P.; Di Francesco, M. E.; Gardelli, C.; Muraglia, E.; Nizi, E.;
Orvieto, F.; Petrocchi, A.; Rowley, M.; Harper, S.; Scarpelli, R.;
Laufer, R.; Gonzalez Paz, O.; Monteagudo, E.; Bonelli, F.; Hazuda,
D.; Stillmock, K. A.; Summa, V. Dihydroxypyrimidine-4-carboxa-
mides as novel potent and selective HIV integrase inhibitors. J. Med.
Chem. 2007, 50, 2225-2239.
(30) Hazuda, D. J.; Hastings, J. C.; Wolfe, A. L.; Emini, E. A. A novel
assay for the DNA strand-transfer reaction of HIV-1 integrase.
Nucleic Acids Res. 1994, 22, 1121-1122.
(31) Wolfe, A. L.; Felock, P. J.; Hastings, J. C.; Blau, C. U.; Hazuda, D.
J. The role of manganese in promoting multimerization and assembly
of human immunodeficiency virus type 1 integrase as a catalytically
active complex on immobilized long terminal repeat substrates. J.
Virol. 1996, 70, 1424-1432.
(32) Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel,
S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth,
E. L-735,524: an orally bioavailable human immunodeficiency virus
type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91,
4096-4100.
(33) Analytical HPLC/UV detection-based assay that measures the ability
of a compound to bind with plasma proteins (primarily albumin) in
pH 7.4 at room temperature.
(34) The concentration of compound 27a was 1 µM and microsomes 1
mg/mL. The degradation of the substrate was measured by LC/MS/
MS during a 1 h incubation.
(35) Butcher, J. W., Claremon, D. A., Connolly, T. M., Dean, D. C.,
Karczewski, J., Koblan, K. S., Kostura M.J., Liverton, N. J., Melillo
D.G. Radioligand and binding assay. PCT Int. Appl. WO 2002
0205860 A1.
(36) Monteagudo, E.; Pesci, S.; Taliani, M.; Fiore, F.; Petrocchi, A.; Nizi,
E.; Rowley, M.; Laufer, R.; Summa, V. Studies of metabolism and
disposition of potent HIV integrase inhibitors using 19F-NMR
spectroscopy. Xenobiotica, 2007, in press.
(37) Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M.
S.; Payne, L. S.; Guare, J. P., Jr.; Vacca, J. P.; Hazuda, D. J.; Felock,
P. J.; Wolfe, A. L.; Stillmock, K. A.; Witmer, M. V.; Moyer, G.;
Schleif, W. A.; Gabryelski, L. J.; Leonard, Y. M.; Lynch, J. J., Jr.;
Michelson, S. R.; Young, S. D. Design and synthesis of 8-hydroxy-
[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro
and in infected cells. J. Med. Chem. 2003, 46, 453-456.
(38) Culbertson, T. P. Synthesis of 5,6-dihydroxy-2-phenyl-4-pyrimidine-
carboxylic acid, methyl ester, a correct structure. J. Heterocycl. Chem.
1979, 16, 1423-1424.
(39) Dreher, S. D.; Ikemoto, N.; Gresham, V.; Liu, J.; Dormer, P. G.;
Balsells, J.; Mathre, D.; Novak, T. J.; Armstrong, J. D. I. Highly
selective synthesis of 2-substituted-5-hydroxy-6-oxo-1,6-dihydropy-
rimidine-4-carboxylic acid derivatives using a novel protected
dihydroxyfumarate. Tetrahedron Lett. 2004, 45, 6023-6025.
(40) Zhong, Y.-L.; Zhou, H.; Gauthier, D. R.; Askin, D. Efficient synthesis
of functionalized pyrimidones via microwave-accelerated reaction.
Tetrahedron Lett. 2006, 47, 1315-1317.
(41) In some runs, >12:1 selectivity was observed. Presence of pyridine
in the Bz-pyrimidine starting material significantly degraded the
regioselectivity. A batch with 1 wt% pyridine gave ∼3:1 selectivity.
Removal of pyridine after the benzoylation step by extracting with
dilute HCl is recommended.
(42) Brown, G. R.; Foubister, A. J.; Wright, B. Chiral synthesis of
3-substituted morpholines via serine enantiomers and reductions of
5-oxomorpholine-3-carboxylate. J. Chem. Soc., Perkin Trans. I 1985,
2577-2580.
(43) De Kimpe, N.; Stevens, C. A convenient synthesis of 6-acetyl-1,2,3,4-
tetrahydropyridine, the principle bread flavor component. J. Org.
Chem. 1993, 58, 2904-2906.
(44) Belleau, B. The synthesis of (+/-), (+), and (-) R-(3-thiamorpholi-
nyl)-benzhydrol, a new selective stimulant of the central nervous
system. J. Med. Pharm. Chem. 1960, 2, 553-562.
(45) Bousquet, Y.; Anderson, P. C.; Bogri, T.; Duceppe, J.-S.; Grenier,
L.; Guse, I. Preparation of enantiopure 4-oxygenated pipecolic acid
derivatives. Tetrahedron 1997, 53, 15671-15680.
(46) Pozdnev, V. F. Activation of carboxylic acids by pyrocarbonates.
Application of di-tert-butyl pyrocarbonate as condensing reagent in
the synthesis of amides of protected aminoacids and peptides.
Tetrahedron Lett. 1995, 36, 7115-7118.
(47) The e.e. were determined by chiral HPLC using a column Chiralpak
AD 250 × 4.6 mm. Eluent n-hexane/ethanol ) 85:15 for compound
85a and n-hexane/isopropanol ) 50:50 for compound 86a; flow rate
) 1 mL/min, λ ) 300 nm.
(48) Manfre`, F.; Kern, J.-M.; Biellmann, J.-F. Synthesis of proline
analogues as potential mechanism-based inhibitors of proline dehy-
drogenase: 4-Methylene-L-, (E)- and (Z)-4-fluoromethylene)-L-, cis-
and trans-5-ethynyl-(+/-)-, and cis- and trans-5-vinyl-L-proline. J.
Org. Chem. 1992, 57, 2060-2065.
(49) Smith, E. M.; Swiss, G. F.; Neustadt, B. R.; Gold, E. H.; Sommer,
J. A.; Brown, A. D.; Chiu, P. J. S.; Moran, R.; Sybertz, E. J.; Baum,
T. Synthesis and pharmacological activity of angiotensin converting
enzyme inhibitors: N-(Mercaptoacyl)-4-substituted- (S)-prolines. J.
Med. Chem. 1988, 31, 875-885.
(50) Demange, L.; Menez, A.; Dugave, C. Practical synthesis of Boc-
and Fmoc-protected 4-fluoro and 4-difluoroprolines from trans-4-
hydroxyproline. Tetrahedron Lett. 1998, 39, 1169-1172.
JM0704705